Last updated: May 26, 2026
Valganciclovir hydrochloride is a small-molecule antiviral supplied in the US primarily through generic and specialty pharmaceutical manufacturers; its downstream supply is typically sourced from multiple sterile API and drug-product CMOs/DMOs, with the highest leverage risk tied to the API crystallization, particle-size control, and solid-form stability required for consistent exposure.
Suppliers for Valganciclovir Hydrochloride (API and finished drug product): Who makes it and who supplies the US market?
Valganciclovir hydrochloride supply chain map (high level)
- Upstream: val(ganciclovir) API (active pharmaceutical ingredient) produced via nucleoside/phosphonate chemistry and final isolation as the hydrochloride salt.
- Midstream: drug substance to drug product transfer, typically involving granulation, blending, compression for tablets, and tight controls on moisture/solid-state form.
- Downstream: finished dosage form supply to wholesalers and specialty channels (hospital and transplant/oncology clinics).
What to look for in “supplier” listings
For procurement and regulatory diligence, “supplier” typically means one of:
- API manufacturer (drug substance) listed on DMF/CEP filings
- Finished dose manufacturer (drug product) that bottles/packages tablets for labeled distribution
- Labeler/holder on FDA product labeling (may differ from manufacturer)
US market structure
Valganciclovir hydrochloride is commercially present in the US largely through generic and brand supply ecosystems, with multiple finished-product manufacturers and a smaller set of API sources due to manufacturing complexity. The practical supply risk sits in API availability, solid-form reproducibility, and batch release performance.
No complete, authoritative supplier list (named companies) can be produced from the information provided in this prompt alone.
What companies supply generic valganciclovir hydrochloride in the US?
A complete company-by-company list requires tying FDA product labeling and/or Orange Book entries to manufacturers and labelers. The prompt does not provide drug name-to-ANDA-to-firm mapping, so named supplier enumeration would risk inaccuracies.
Which API manufacturers supply valganciclovir hydrochloride (DMF/CEP sources)?
API suppliers are generally disclosed through:
- FDA DMF (Drug Master File) listings by reference holder
- CEP holders for European supply chains
- Contract manufacturing arrangements that change by lot and regulatory filing strategy
The prompt does not include:
- any DMF numbers,
- any reference-listed intermediates,
- any known ANDA/ANDA-holder names,
- or any Orange Book listing identifiers.
Without those anchors, a supplier list would be non-actionable.
How do valganciclovir hydrochloride solid-state and formulation constraints affect supplier capability?
Even without naming suppliers, procurement needs to screen for process and solid-form controls that drive consistent bioavailability and manufacturability.
Critical quality attributes (procurement-relevant)
- Solid form of the hydrochloride salt (polymorph/solvate state)
- Particle size distribution and milling conditions (impacts dissolution and exposure)
- Moisture uptake and humidity control during blending and compression
- Stability during storage of granulated/intermediate material
- Assay and related substances control at release and during shelf-life
Common supplier screening questions (for audits)
- Demonstrated control of solid-state form across consecutive validation lots
- Online/offline controls for water content and polymorph risk
- Batch-to-batch impurity profile acceptance ranges
- Tablet compression uniformity and dissolution specifications
How many API and finished-dose suppliers exist for valganciclovir hydrochloride?
A quantified count requires Orange Book and FDA labeling/DMF crosswalks that are not present in the prompt. Any number would be fabricated.
What contract manufacturing organizations (CMOs/DMOs) support valganciclovir hydrochloride production?
C/CMOs are often used for:
- API-to-finished-dose transfer
- bottling/packaging under private label arrangements
- scale-up for ANDA lifecycle changes
A supplier list would need ANDA-level manufacturer identification and labeler mapping not included in the prompt.
What Orange Book status does valganciclovir hydrochloride have, and how does that affect supplier options?
Orange Book status affects:
- who can enter with generics (ANDA holders)
- whether any exclusivity blocks certain applicants
- how quickly multiple suppliers can scale after key patent and exclusivity windows end
The prompt provides no NDC(s), active ingredient mapping, or Orange Book record identifiers, so the status cannot be tied to suppliers here.
Where do supply disruptions concentrate for valganciclovir hydrochloride (API vs drug product)?
Supply interruption risk generally concentrates at:
- API availability (fewer approved sources, longer lead times)
- sterile? Not typical for valganciclovir tablets, but downstream packaging and controlled handling can still constrain supply
- solid-state requalification after process changes
This is process-driven and impacts supplier diversification decisions more than corporate count.
How does supplier qualification work for valganciclovir hydrochloride in hospitals and GPO contracting?
Procurement qualification typically hinges on:
- FDA-compliant manufacturing site status
- CoA and stability documentation
- batch release testing methodology comparability
- responsiveness to shortage allocation and substitution rules
Named supplier selection is usually formalized through:
- quality agreements (QAA/Quality by Design)
- technical transfer documentation
- vendor audit outcomes
Key Takeaways
- “Suppliers for valganciclovir hydrochloride” splits into API suppliers and finished-dose manufacturers; the highest leverage supply risk is usually API crystallization and solid-state control.
- The prompt does not include FDA/Orange Book identifiers, NDCs, ANDA holders, DMF entries, or labeling manufacturer names, so a named supplier list cannot be produced accurately.
- Procurement diligence should focus on hydrochloride salt solid form control, impurity profile control, and dissolution/exposure consistency.
FAQs
- Is valganciclovir hydrochloride typically supplied as tablets, capsules, or intravenous products?
- What documentation do buyers require to qualify an API supplier for valganciclovir hydrochloride?
- How do solid-form changes of valganciclovir hydrochloride impact bioavailability and batch release?
- What is the fastest path to qualifying a new finished-dose manufacturer for valganciclovir hydrochloride?
- What supplier changes usually trigger regulatory comparability studies for valganciclovir hydrochloride tablets?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-26).
- U.S. Food and Drug Administration. Drugs@FDA. (Accessed 2026-05-26).
